Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study

Authors: Kaidi Mikhitarian, Renee Hebert Martin, Megan Baker Ruppel, William E Gillanders, Rana Hoda, Del H Schutte, Kathi Callahan, Michael Mitas, David J Cole

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

We sought to examine the detection rate of cancer cells in peripheral blood (PBL) and in bone marrow (BM) using an established 7-gene marker panel and evaluated whether there were any definable associations of any individual gene with traditional predictors of prognosis.

Methods

Patients with T1-T3 primary breast cancer were enrolled into a prospective, multi-institutional cohort study. In this interim analysis 215 PBL and 177 BM samples were analyzed by multimarker, real-time RT-PCR analysis designed to detect circulating and disseminated breast cancer cells.

Results

At a threshold of three standard deviations from the mean expression level of normal controls, 63% (136/215) of PBL and 11% (19/177) of BM samples were positive for at least one cancer-associated marker. Marker positivity in PBL demonstrated a statistically significant association with grade II-III (vs. grade I; p = 0.0083). Overexpression of the mammaglobin (mam) gene alone had a statistically significant association with high tumor grade (p = 0.0315), and showed a trend towards ER-negative tumors and a high risk category. There was no association between marker positivity in PBL and the pathologic (H&E) and/or molecular (RT-PCR) status of the axillary lymph nodes (ALN).

Conclusion

This study suggests that molecular detection of circulating cancer cells in PBL detected by RT-PCR is associated with high tumor grade and specifically that overexpression of the mam gene in PBL may be a poor prognostic indicator. There was no statistically significant association between overexpression of cancer-associated genes in PBL and ALN status, supporting the concept of two potentially separate metastatic pathways.
Appendix
Available only for authorised users
Literature
1.
Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K: A pooled analysis of bone marrow micrometastasis in breast cancer. The New England journal of medicine. 2005, 353 (8): 793-802. 10.1056/NEJMoa050434.CrossRefPubMed
2.
Yu JJ, Brennan M, Christos P, Osborne MP, Hoda S, Simmons RM: Bone marrow micrometastases and adjuvant treatment of breast cancer. The breast journal. 2004, 10 (3): 181-185. 10.1111/j.1075-122X.2004.21292.x.CrossRefPubMed
3.
Trocciola SM, Hoda S, Osborne MP, Christos PJ, Levin H, Martins D, Carson J, Daly J, Simmons RM: Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients?. Journal of the American College of Surgeons. 2005, 200 (5): 720-5; discussion 725-6. 10.1016/j.jamcollsurg.2004.12.029.CrossRefPubMed
4.
Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC: Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. International journal of cancer. 2005, 114 (1): 94-100. 10.1002/ijc.20655.CrossRefPubMed
5.
Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H: Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res. 2004, 10 (4): 1392-1400. 10.1158/1078-0432.CCR-0102-03.CrossRefPubMed
6.
Benoy IH, Elst H, Van der Auwera I, Van Laere S, van Dam P, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY: Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. British journal of cancer. 2004, 91 (10): 1813-1820. 10.1038/sj.bjc.6602189.CrossRefPubMedPubMedCentral
7.
Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF: Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer research. 2005, 25 (3B): 2171-2175.PubMed
8.
Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K: Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 2005, 11 (10): 3678-3685. 10.1158/1078-0432.CCR-04-2469.CrossRefPubMed
9.
Bauernhofer T, Zenahlik S, Hofmann G, Balic M, Resel M, Pirchmoser R, Regitnig P, Ambros P, Dandachi N, Samonigg H: Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncology reports. 2005, 13 (2): 179-184.PubMed
10.
Taubert H, Blumke K, Bilkenroth U, Meye A, Kutz A, Bartel F, Lautenschlager C, Ulbrich EJ, Nass N, Holzhausen HJ, Koelbl H, Lebrecht A: Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gynecologic oncology. 2004, 92 (1): 256-261. 10.1016/j.ygyno.2003.09.009.CrossRefPubMed
11.
Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M, de la Torre N, Algarra I, Duenas R, Lozano A: Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. International journal of cancer. 2003, 107 (6): 984-990. 10.1002/ijc.11479.CrossRefPubMed
12.
Janku F, Kleibl Z, Novotny J, Tesarova P, Petruzelka L, Matous B: Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma. 2004, 51 (3): 204-208.PubMed
13.
Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E, Vermeulen PB, Dirix LY: Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. British journal of cancer. 2006, 94 (5): 672-680.PubMedPubMedCentral
14.
Ooka M, Tamaki Y, Sakita I, Fujiwara Y, Yamamoto H, Miyake Y, Sekimoto M, Ohue M, Sugita Y, Miyoshi Y, Ikeda N, Noguchi S, Monden M: Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast cancer research and treatment. 2001, 67 (2): 169-175. 10.1023/A:1010651632354.CrossRefPubMed
15.
Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V: Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res. 2004, 10 (24): 8185-8194. 10.1158/1078-0432.CCR-03-0094.CrossRefPubMed
16.
Masuda TA, Kataoka A, Ohno S, Murakami S, Mimori K, Utsunomiya T, Inoue H, Tsutsui S, Kinoshita J, Masuda N, Moriyama N, Mori M: Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. International journal of oncology. 2005, 26 (3): 721-730.PubMed
17.
Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P: Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. International journal of cancer. 2005, 114 (2): 291-298. 10.1002/ijc.20698.CrossRefPubMed
18.
Benoy IH, Salgado R, Elst H, Van Dam P, Weyler J, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY: Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res. 2005, 7 (2): R210-9. 10.1186/bcr980.CrossRefPubMedPubMedCentral
19.
Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P, Van Oosterom AT: Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin Cancer Res. 2004, 10 (1 Pt 1): 196-201. 10.1158/1078-0432.CCR-0515-2.CrossRefPubMed
20.
Roncella S, Ferro P, Bacigalupo B, Pronzato P, Tognoni A, Falco E, Gianquinto D, Ansaldo V, Dessanti P, Fais F, Rosai J, Fedeli F: Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. J Exp Clin Cancer Res. 2005, 24 (2): 265-271.PubMed
21.
Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, Gaudio M, Frassineti GL, Amadori D, Flamini E: RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann Oncol. 2006, 17 (3): 424-428. 10.1093/annonc/mdj109.CrossRefPubMed
22.
Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V: Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. International journal of cancer. 2004, 108 (4): 620-627. 10.1002/ijc.11593.CrossRefPubMed
23.
Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V: Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol. 2005, 16 (2): 240-246. 10.1093/annonc/mdi043.CrossRefPubMed
24.
Cerveira N, Torres L, Rocha P, Bizarro S, Pereira D, Abreu J, Henrique R, Teixeira MR, Castedo S: Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. International journal of cancer. 2004, 108 (4): 592-595. 10.1002/ijc.11609.CrossRefPubMed
25.
Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ: Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. British journal of cancer. 2003, 88 (7): 1091-1094. 10.1038/sj.bjc.6600868.CrossRefPubMedPubMedCentral
26.
Fabisiewicz A, Kulik J, Kober P, Brewczynska E, Pienkowski T, Siedlecki JA: Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. Acta biochimica Polonica. 2004, 51 (3): 747-755.PubMed
27.
Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, Brescia F, Kneuper-Hall R, Mitas M, Cole DJ, Gillanders WE: Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res. 2003, 9 (13): 4865-4871.PubMed
28.
Zehentner BK, Persing DH, Deme A, Toure P, Hawes SE, Brooks L, Feng Q, Hayes DC, Critichlow CW, Houghton RL, Kiviat NB: Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clinical chemistry. 2004, 50 (11): 2069-2076. 10.1373/clinchem.2004.038687.CrossRefPubMedPubMedCentral
29.
Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M: Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. British journal of cancer. 2005, 92 (5): 906-912. 10.1038/sj.bjc.6602418.CrossRefPubMedPubMedCentral
30.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England journal of medicine. 2004, 351 (8): 781-791. 10.1056/NEJMoa040766.CrossRefPubMed
31.
Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z, Gillanders WE, Cole DJ: Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. International journal of cancer. 2001, 93 (2): 162-171. 10.1002/ijc.1312.CrossRefPubMed
32.
Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI, Gillanders WE: Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003, 5 (4): 237-242.CrossRefPubMedPubMedCentral
33.
Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Metcalf JS, Elliott BM, Brothers T, Robison J, Mitas M, Cole DJ: Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Annals of surgery. 2004, 239 (6): 828-37; discussion 837-40. 10.1097/01.sla.0000128687.59439.d6.CrossRefPubMedPubMedCentral
34.
Mikhitarian K, Martin RH, Mitas M, Mauldin PD, Palesch Y, Metcalf JS, Cole DJ, Gillanders WE: Molecular analysis improves sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study. Surgery. 2005, 138 (3): 474-481. 10.1016/j.surg.2005.07.001.CrossRefPubMed
35.
Mitas M, Almeida JS, Mikhitarian K, Gillanders WE, Lewin DN, Spyropoulos DD, Hoover L, Graham A, Glenn T, King P, Cole DJ, Hawes R, Reed CE, Hoffman BJ: Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res. 2005, 11 (6): 2205-2214. 10.1158/1078-0432.CCR-04-1091.CrossRefPubMed
36.
Mitas M, Mikhitarian K, Hoover L, Lockett MA, Kelley L, Hill A, Gillanders WE, Cole DJ: Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. British journal of cancer. 2002, 86 (6): 899-904. 10.1038/sj.bjc.6600190.CrossRefPubMedPubMedCentral
37.
Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer research. 2004, 64 (16): 5818-5824. 10.1158/0008-5472.CAN-04-0754.CrossRefPubMed
38.
Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981, 29 (4): 577-580.CrossRefPubMed
39.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001, 19 (18): 3817-3827.PubMed
40.
Ruud P, Fodstad O, Hovig E: Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. International journal of cancer. 1999, 80 (1): 119-125. 10.1002/(SICI)1097-0215(19990105)80:1<119::AID-IJC22>3.0.CO;2-X.CrossRefPubMed
41.
Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D: Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol. 1999, 17 (7): 2015-2019.PubMed
42.
Grunewald K, Haun M, Urbanek M, Fiegl M, Muller-Holzner E, Gunsilius E, Dunser M, Marth C, Gastl G: Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Laboratory investigation; a journal of technical methods and pathology. 2000, 80 (7): 1071-1077.CrossRefPubMed
43.
Lin YC, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, Liaw IC, Cheng AJ: Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer science. 2003, 94 (1): 99-102. 10.1111/j.1349-7006.2003.tb01359.x.CrossRefPubMed
44.
Zach O, Kasparu H, Wagner H, Krieger O, Lutz D: Mammaglobin as a marker for the detection of tumor cells in the peripheral blood of breast cancer patients. Annals of the New York Academy of Sciences. 2000, 923: 343-345.CrossRefPubMed
45.
Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002, 20 (16): 3404-3412. 10.1200/JCO.2002.08.135.CrossRefPubMed
Metadata
Title
Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study
Authors
Kaidi Mikhitarian
Renee Hebert Martin
Megan Baker Ruppel
William E Gillanders
Rana Hoda
Del H Schutte
Kathi Callahan
Michael Mitas
David J Cole
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-55

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro

Technical advance

Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR

Research article

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer

Research article

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

Research article

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

Study protocol

ProsCan for Couples: Randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer who receive radical prostatectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits